IN2012DN01708A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01708A IN2012DN01708A IN1708DEN2012A IN2012DN01708A IN 2012DN01708 A IN2012DN01708 A IN 2012DN01708A IN 1708DEN2012 A IN1708DEN2012 A IN 1708DEN2012A IN 2012DN01708 A IN2012DN01708 A IN 2012DN01708A
- Authority
- IN
- India
- Prior art keywords
- tumors
- folate
- ovarian
- methods
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
FOLATE-TARGETED DIAGNOSTICS AND TREATMENT Methods of detecting and assessing functionally active folate receptors on tumors and treatment associated with those tumors are described. Also described are methods of selecting ovarian and lung cancer patients for therapy with a folate-vinca conjugate by identifying functionally active folate receptors on the tumors of the patient. Also described are methods and compositions for treating folate receptor expressing epithelial tumors with a folate-vinca conjugate in combination with doxorubicin such as pegylated liposomal doxorubicin in which the tumors include ovarian endometrial or non-small cell lung cancer tumors including platinum-resistant ovarian tumors and platinum sensitive ovarian tumors. Also described are methods of treating platinum-resistant ovarian cancer using a folate-targeted drug in the absence or presence of selecting the patient by identifying functionally active folate receptors on the tumors of the patient.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23059509P | 2009-07-31 | 2009-07-31 | |
US34644410P | 2010-05-19 | 2010-05-19 | |
US35102210P | 2010-06-03 | 2010-06-03 | |
PCT/US2010/043992 WO2011014821A1 (en) | 2009-07-31 | 2010-07-30 | Folate-targeted diagnostics and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01708A true IN2012DN01708A (en) | 2015-06-05 |
Family
ID=43529728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1708DEN2012 IN2012DN01708A (en) | 2009-07-31 | 2010-07-30 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20120128587A1 (en) |
EP (1) | EP2460013A4 (en) |
JP (1) | JP2013501224A (en) |
KR (1) | KR20120050462A (en) |
CN (2) | CN104857534A (en) |
AU (1) | AU2010278734A1 (en) |
BR (1) | BR112012002064A2 (en) |
CA (1) | CA2769754A1 (en) |
IL (1) | IL217744A0 (en) |
IN (1) | IN2012DN01708A (en) |
NZ (1) | NZ598145A (en) |
RU (1) | RU2012105641A (en) |
WO (1) | WO2011014821A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2187965B1 (en) | 2007-08-17 | 2019-10-09 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
MX2013005194A (en) | 2010-11-12 | 2013-06-28 | Endocyte Inc | Methods of treating cancer. |
EP2696684A4 (en) * | 2011-04-12 | 2014-11-05 | Endocyte Inc | Solid pharmaceutical composition |
US9636413B2 (en) | 2012-11-15 | 2017-05-02 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
EP3057619A1 (en) | 2013-10-16 | 2016-08-24 | Université Libre de Bruxelles | Formulations useful in the treatment of proliferative diseases affecting the respiratory tract |
EA037778B1 (en) | 2013-10-18 | 2021-05-20 | Дойчес Кребсфоршунгсцентрум | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
ES2745799T3 (en) | 2013-11-19 | 2020-03-03 | Purdue Research Foundation | Patient selection method for inflammation |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US20170368208A1 (en) * | 2015-01-11 | 2017-12-28 | Endocyte, Inc. | Cancer imaging agent |
IL237525A (en) | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen ligand with a radioactive isotope |
EP3600430A4 (en) * | 2016-03-29 | 2020-12-30 | Endocyte, Inc. | Folate conjugate for use in targeting tumor associated macrophages |
US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
EP3463367A4 (en) * | 2016-05-25 | 2020-01-29 | Purdue Research Foundation | Method of treating cancer by targeting myeloid-derived suppressor cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI492750B (en) * | 2003-01-27 | 2015-07-21 | 安德賽特公司 | Vitamin-receptor binding drug delivery conjugates, pharmaceutical compositions, uses and preparation processes |
KR101320936B1 (en) * | 2004-12-21 | 2013-10-23 | 넥타르 테라퓨틱스 | Stabilized polymeric thiol reagents |
EP2452695A3 (en) * | 2004-12-23 | 2013-01-23 | Purdue Research Foundation | Positron emission tomography imaging method |
JP5289935B2 (en) * | 2005-03-16 | 2013-09-11 | エンドサイト,インコーポレイテッド | Synthesis and purification of pteroic acid and its conjugates |
AU2006230219A1 (en) * | 2005-03-30 | 2006-10-05 | Endocyte, Inc. | Method for cancer prognosis using cellular folate vitamin receptor quantification |
JP2006316040A (en) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(r) adjuvant treatment |
JP2010507659A (en) * | 2006-10-25 | 2010-03-11 | シェーリング コーポレイション | How to treat ovarian cancer |
ES2732879T3 (en) * | 2007-06-25 | 2019-11-26 | Endocyte Inc | Conjugates containing hydrophilic spacer linkers |
-
2010
- 2010-07-30 RU RU2012105641/15A patent/RU2012105641A/en not_active Application Discontinuation
- 2010-07-30 CN CN201510160314.2A patent/CN104857534A/en active Pending
- 2010-07-30 BR BR112012002064A patent/BR112012002064A2/en not_active IP Right Cessation
- 2010-07-30 CN CN2010800434602A patent/CN102549434A/en active Pending
- 2010-07-30 IN IN1708DEN2012 patent/IN2012DN01708A/en unknown
- 2010-07-30 AU AU2010278734A patent/AU2010278734A1/en not_active Abandoned
- 2010-07-30 KR KR1020127005358A patent/KR20120050462A/en not_active Application Discontinuation
- 2010-07-30 EP EP10805137A patent/EP2460013A4/en not_active Withdrawn
- 2010-07-30 CA CA2769754A patent/CA2769754A1/en not_active Abandoned
- 2010-07-30 NZ NZ598145A patent/NZ598145A/en not_active IP Right Cessation
- 2010-07-30 US US13/388,184 patent/US20120128587A1/en not_active Abandoned
- 2010-07-30 WO PCT/US2010/043992 patent/WO2011014821A1/en active Application Filing
- 2010-07-30 JP JP2012523104A patent/JP2013501224A/en active Pending
-
2012
- 2012-01-26 IL IL217744A patent/IL217744A0/en unknown
-
2013
- 2013-03-13 US US13/800,309 patent/US20140140925A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL217744A0 (en) | 2012-03-29 |
AU2010278734A1 (en) | 2012-02-23 |
WO2011014821A1 (en) | 2011-02-03 |
US20140140925A1 (en) | 2014-05-22 |
KR20120050462A (en) | 2012-05-18 |
CA2769754A1 (en) | 2011-02-03 |
EP2460013A1 (en) | 2012-06-06 |
CN104857534A (en) | 2015-08-26 |
RU2012105641A (en) | 2013-09-10 |
NZ598145A (en) | 2014-10-31 |
BR112012002064A2 (en) | 2017-05-09 |
US20120128587A1 (en) | 2012-05-24 |
CN102549434A (en) | 2012-07-04 |
JP2013501224A (en) | 2013-01-10 |
EP2460013A4 (en) | 2013-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01708A (en) | ||
Martin et al. | Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine | |
WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
CY1118325T1 (en) | ANALYSIS OF ANTI-CANCER UNITS THROUGH THE ACTIVITY OF NETRIN-1 | |
WO2014036495A3 (en) | Diagnostic assays and kits for detection of folate receptor 1 | |
WO2019094692A3 (en) | Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment | |
CY1118566T1 (en) | DIAGNOSIS USING INTERFERENCE TYPE 1 | |
MX347893B (en) | Human antibody drug conjugates against tissue factor. | |
MX2009012722A (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment. | |
EP4356960A3 (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
Roper et al. | Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer | |
MX2014005800A (en) | Human notch receptor mutations and their use. | |
Felip et al. | Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer | |
PH12014502399A1 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
EA201291260A1 (en) | ANTIBODY AGAINST TROP-2 PERSON HAS ANTI-TUMOR ACTIVITY IN VIVO | |
CR10940A (en) | VEGF SPECIFIC ANTAGONISTS FOR ADJUTIVE AND NEOADJUTIVE THERAPY AND TUMOR TREATMENT IN EARLY STAYS | |
MX2019000425A (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer. | |
PL2223115T3 (en) | Seprase as a marker for cancer | |
MX340724B (en) | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer. | |
EP2527466A3 (en) | Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
Perry et al. | A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP | |
WO2011087709A3 (en) | Eml4-alk translocations in lung cancer | |
MX2013011431A (en) | Methods for predicting and improving the survival of gastric cancer patients. | |
MY172580A (en) | Tumor tissue based biomarkers for bevacizumab combination therapies | |
NZ707116A (en) | Ly75 as cancer therapeutic and diagnostic target |